PCSK9 Inhibitor Reduced Cardiovascular Disease Risk in T2D Patients
Patients with type 2 diabetes taking alirocumab (Praluent), along with the maximum tolerable dose of statins, saw a 49% drop in low-density lipoprotein cholesterol during a recent study.